Neurizon completes enrolment in ALS trial, bringing topline results forward
NUZ: $0.086 +0.00% · MC: $48M
Neurizon Therapeutics completed enrolment of 250 participants in the HEALEY ALS trial, bringing the anticipated topline readout forward to late Q2 2027. The FDA said the trial could potentially serve as the single study supporting a traditional approval application, subject to results meeting effectiveness requirements; an NIH grant will fund an expanded-access program for up to 200 people with ALS. Neurizon reported cash of $11 million at quarter-end and said it remains funded through the trial readout.

Comments